Logo image
Back
COVID-19 breakthrough infections in rheumatic diseases patients after vaccination
Journal article   Open access   Peer reviewed

COVID-19 breakthrough infections in rheumatic diseases patients after vaccination

Abeer N. Alshukairi, Awad Al-Omari, Abdurahman Albeity, Thamir A. Alandijany, Ahmed M. Hassan, Sherif A. El-Kafrawy, Ashraf Dada, Mohammad K. Al Hroub, Aiman El-Saed, Lina S. Bissar, …
Journal of infection and public health, Vol.15(6), pp.685-688
06/2022
DOI: 10.1016/j.jiph.2022.05.005
PMCID: PMC9098803
PMID: 35623243
url
https://doi.org/10.1016/j.jiph.2022.05.005View
Published (Version of record) Open Access

Abstract

Rheumatic diseases patients receiving Rituximab had severe COVID-19 disease. Although they had impaired humoral immune responses following COVID-19 vaccine, they had preserved cellular immune responses. Waning of COVID-19 antibody responses was observed within six months post vaccination among immunocompromised patients. Recent reports showed fatal outcome of breakthrough SARS-CoV-2 infections among vaccinated high-risk rheumatic diseases patients receiving Rituximab. SAR-CoV-2 serological tests were not performed. Evaluation of COVID-19 vaccine humoral responses and breakthrough infections among low risk fully vaccinated rheumatic patients during the Delta Variant Era. A case series of 19 fully vaccinated patients with rheumatic diseases were followed to determine post vaccine SARS-CoV-2 neutralizing antibody titers and to monitor the development of breakthrough infections up to eight months post vaccine at our tertiary care center in Jeddah, Saudi Arabia from 1st April until 30th November 2021. The mean age of patients was 49 years old. 10% of patients were receiving Rituximab. 73% of patients had positive SARS-CoV-2 serological testing post second vaccine. Two mild breakthrough COVID-19 infections were diagnosed six months post second dose of vaccine. Patients were less than 65 years, did not receive Rituximab, did not have interstitial lung diseases and had positive post vaccine serological testing. We demonstrated high SARS-CoV-2 neutralizing antibodies seroprevalence and self-limiting breakthrough infections in low risk rheumatic diseases patients during the Delta Era. Future studies are needed to study the outcome of rheumatic diseases patients in the Era of Omicron in view of viral immune escape responses.
 Breakthrough infection COVID-19 Outcome Rheumatic diseases Vaccine

Details

Metrics

14 Record Views
3 Times Cited - Web of Science
Logo image